for signs of bleeding. iloperidonediphenhydramine will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and iloperidone both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.diphenhydramine decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.iloperidone increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.imatinibimatinib will increase the level or effect of ibuprofen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.imatinib, ibuprofen. Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents.imipraminediphenhydramine will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and imipramine both increase sedation. Use Caution/Monitor.indapamideibuprofen increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.indomethacinibuprofen and indomethacin both increase anticoagulation. Use Caution/Monitor.ibuprofen and indomethacin both increase serum potassium. Use Caution/Monitor.ipratropiumdiphenhydramine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.irbesartanirbesartan and ibuprofen both increase serum potassium. Use Caution/Monitor.ibuprofen decreases effects of irbesartan by pharmacodynamic antagonism. Use Caution/Monitor. Antihypertensive effect of angiotensin receptor blockers may be attenuated by NSAIDs; monitor renal function and blood pressure periodically.irbesartan, ibuprofen. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.isoproterenoldiphenhydramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ibuprofen increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.kavakava increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.ketoprofenibuprofen and ketoprofen both increase anticoagulation. Use Caution/Monitor.ibuprofen and ketoprofen both increase serum potassium. Use Caution/Monitor.ketamineketamine and diphenhydramine both increase sedation. Use Caution/Monitor.ketorolacibuprofen and ketorolac both increase anticoagulation. Use Caution/Monitor.ibuprofen and ketorolac both increase serum potassium. Use Caution/Monitor.ketorolac intranasalibuprofen and ketorolac intranasal both increase anticoagulation. Use Caution/Monitor.ibuprofen and ketorolac intranasal both increase serum potassium. Use Caution/Monitor.ketotifen, ophthalmicdiphenhydramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.labetalollabetalol and ibuprofen both increase serum potassium. Use Caution/Monitor.ibuprofen decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs diminish antihypertensive effects of beta-blockers.lacosamideibuprofen increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.lasmiditanlasmiditan, diphenhydramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.latanoprostlatanoprost, ibuprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).latanoprostene bunod ophthalmiclatanoprostene bunod ophthalmic, ibuprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).lemborexantlemborexant, diphenhydramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.lesinuradibuprofen will increase the level or effect of lesinurad by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.levalbuterolibuprofen increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.diphenhydramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levodopadiphenhydramine, levodopa. Other (see comment). Use Caution/Monitor. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .levofloxacinlevofloxacin, ibuprofen. Other (see comment). Modify Therapy/Monitor Closely. Comment: Risk of CNS stimulation/seizure. Mechanism: Displacement of GABA from receptors in brain.levomilnacipranlevomilnacipran, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs.levorphanoldiphenhydramine and levorphanol both increase sedation. Use Caution/Monitor.lisdexamfetaminediphenhydramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lisinoprillisinopril, ibuprofen. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.lithiumibuprofen increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.lofepraminediphenhydramine will increase the level or effect of lofepramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and lofepramine both increase sedation. Use Caution/Monitor.lofexidinediphenhydramine and lofexidine both increase sedation. Use Caution/Monitor.loprazolamdiphenhydramine and loprazolam both increase sedation. Use Caution/Monitor.lorazepamdiphenhydramine and lorazepam both increase sedation. Use Caution/Monitor.lormetazepamdiphenhydramine and lormetazepam both increase sedation. Use Caution/Monitor.lornoxicamibuprofen and lornoxicam both increase anticoagulation. Use Caution/Monitor.ibuprofen and lornoxicam both increase serum potassium. Use Caution/Monitor.losartanlosartan and ibuprofen both increase serum potassium. Use Caution/Monitor.ibuprofen decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.losartan, ibuprofen. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.loxapinediphenhydramine and loxapine both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.diphenhydramine decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.loxapine inhaledloxapine inhaled increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diphenhydramine and loxapine inhaled both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.lumacaftor/ivacaftorlumacaftor/ivacaftor will decrease the level or effect of ibuprofen by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Ibuprofen it a substrate of CYP2C9. Lumacaftor has the potential to induce CYP2C9 substrates.lurasidonelurasidone, diphenhydramine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilinediphenhydramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and maprotiline both increase sedation. Use Caution/Monitor.marijuanadiphenhydramine and marijuana both increase sedation. Use Caution/Monitor.meclizinediphenhydramine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.meclofenamatemeclofenamate and ibuprofen both increase anticoagulation. Use Caution/Monitor.meclofenamate and ibuprofen both increase serum potassium. Use Caution/Monitor.mefenamic acidibuprofen and mefenamic acid both increase anticoagulation. Use Caution/Monitor.ibuprofen and mefenamic acid both increase serum potassium. Use Caution/Monitor.melatoninmelatonin increases effects of ibuprofen by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time.diphenhydramine and melatonin both increase sedation. Use Caution/Monitor.meloxicamibuprofen and meloxicam both increase anticoagulation. Use Caution/Monitor.ibuprofen and meloxicam both increase serum potassium. Use Caution/Monitor.meperidinediphenhydramine and meperidine both increase sedation. Use Caution/Monitor.meprobamatediphenhydramine and meprobamate both increase sedation. Use Caution/Monitor.mesalaminemesalamine, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity.metaproterenolibuprofen increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.diphenhydramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxalonediphenhydramine and metaxalone both increase sedation. Use Caution/Monitor.methyclothiazideibuprofen increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .methadonediphenhydramine and methadone both increase sedation. Use Caution/Monitor.methamphetaminediphenhydramine will increase the level or effect of methamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methocarbamoldiphenhydramine and methocarbamol both increase sedation. Use Caution/Monitor.methscopolaminediphenhydramine and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.methylenedioxymethamphetaminediphenhydramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methylprednisoloneibuprofen, methylprednisolone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.metolazoneibuprofen increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.metoprololmetoprolol and ibuprofen both increase serum potassium. Use Caution/Monitor.diphenhydramine will increase the level or effect of metoprolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.ibuprofen decreases effects of metoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.mexiletinediphenhydramine will increase the level or effect of mexiletine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.milnacipranmilnacipran, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.midazolamdiphenhydramine and midazolam both increase sedation. Use Caution/Monitor.midazolam intranasalmidazolam intranasal, diphenhydramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.midodrinediphenhydramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mipomersenmipomersen, ibuprofen. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.mirtazapinediphenhydramine and mirtazapine both increase sedation. Use Caution/Monitor.mistletoeibuprofen increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.modafinildiphenhydramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.moexiprilmoexipril, ibuprofen. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.morphinediphenhydramine will increase the level or effect of morphine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and morphine both increase sedation. Use Caution/Monitor.motherwortdiphenhydramine and motherwort both increase sedation. Use Caution/Monitor.moxifloxacinmoxifloxacin, ibuprofen. Other (see comment). Modify Therapy/Monitor Closely. Comment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.moxisylyteibuprofen decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.moxonidinediphenhydramine and moxonidine both increase sedation. Use Caution/Monitor.mycophenolateibuprofen will increase the level or effect of mycophenolate by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.nabilonediphenhydramine and nabilone both increase sedation. Use Caution/Monitor.nabumetoneibuprofen and nabumetone both increase anticoagulation. Use Caution/Monitor.ibuprofen and nabumetone both increase serum potassium. Use Caution/Monitor.nadololnadolol and ibuprofen both increase serum potassium. Use Caution/Monitor.ibuprofen decreases effects of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.nalbuphinediphenhydramine and nalbuphine both increase sedation. Use Caution/Monitor.nebivololnebivolol and ibuprofen both increase serum potassium. Use Caution/Monitor.ibuprofen decreases effects of nebivolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.diphenhydramine will increase the level or effect of nebivolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.nefazodonenefazodone, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.neostigmineneostigmine increases and diphenhydramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.nettleibuprofen increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.norepinephrineibuprofen increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.diphenhydramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.nortriptylinediphenhydramine will increase the level or effect of nortriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.diphenhydramine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and nortriptyline both increase sedation. Use Caution/Monitor.olmesartanolmesartan and ibuprofen both increase serum potassium. Use Caution/Monitor.ibuprofen decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.olmesartan, ibuprofen. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.olanzapinediphenhydramine and olanzapine both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.diphenhydramine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.oliceridinediphenhydramine will increase the level or effect of oliceridine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. onabotulinumtoxinAonabotulinumtoxinA and diphenhydramine both decrease cholinergic effects/transmission. Use Caution/Monitor.opium tincturediphenhydramine and opium tincture both increase sedation. Use Caution/Monitor.orphenadrinediphenhydramine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and orphenadrine both increase sedation.